News
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Key Points
- Interested in Cardiol Therapeutics Inc.? Here are five stocks we like better.
- Cardiol Therapeutics is advancing CardiolRx into the pivotal Phase III MAVERIC trial for preventing
EQS-News: Formycon berichtet über wichtige operative Erfolge im ersten Halbjahr 2026 und zeigt deutlich verbesserte Finanzzahlen im Vergleich zum Vorjahreszeitraum
EQS-News: Formycon berichtet über wichtige operative Erfolge im ersten Halbjahr 2026 und zeigt deutlich verbesserte Finanzzahlen im Vergleich zum Vorjahreszeitraum
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure is targeting $1 billion in revenue by 2030, after reporting roughly 18% five-year compound growth, a 77%
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
Key Points
- Interested in AngioDynamics, Inc.? Here are five stocks we like better.
- MedTech is expected to become AngioDynamics’ majority revenue source in fiscal 2027, rising from 47% of
LENZ Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in LENZ Therapeutics, Inc.? Here are five stocks we like better.
- Q2 revenue reached $5.5 million, including more than $1.7 million in VIZZ product revenue and $3.8
Codexis Q2 Earnings Call Highlights
Key Points
- Interested in Codexis, Inc.? Here are five stocks we like better.
- Codexis reported Q2 revenue of $14.9 million, down slightly from $15.3 million a year earlier, while net loss
JBS Q2 Earnings Call Highlights
Key Points
- Interested in Jbs N.V.? Here are five stocks we like better.
- JBS reported record second-quarter sales of $24 billion, with adjusted EBITDA of $1.43 billion under IFRS and adjusted net
Lightwave Logic Q2 Earnings Call Highlights
Key Points
- Interested in Lightwave Logic Inc.? Here are five stocks we like better.
- Commercialization advanced: Lightwave Logic expanded its Stage 3 customer programs to five, including a
PLBY Group Q2 Earnings Call Highlights
Key Points
- Interested in PLBY Group, Inc.? Here are five stocks we like better.
- PLBY Group returned to profitability in Q2: Revenue rose 10.9% year over year to $31.2 million, adjusted EBITDA
Valneva Aktie: H1-Ergebnisse am Donnerstag erwartet
Am kommenden Donnerstag wird es für die Aktionäre von Valneva ernst. Das Unternehmen plant…
Der Beitrag Valneva Aktie: H1-Ergebnisse am Donnerstag erwartet erschien zuerst auf kapitalmarktexperten.d
RadNet Q2 Earnings Call Highlights
Key Points
- Interested in RadNet, Inc.? Here are five stocks we like better.
- RadNet delivered record Q2 results: Revenue rose 25% year over year to $622.7 million and adjusted EBITDA increased
Axsome Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Axsome Therapeutics, Inc.? Here are five stocks we like better.
- Q2 revenue rose 46% year over year to $218 million, led by AUVELITY sales of $180.3 million, while the
WSP Global Q2 Earnings Call Highlights
Key Points
- Interested in WSP Global Inc.? Here are five stocks we like better.
- WSP delivered a strong second quarter: Net revenue rose about 23% year over year, adjusted EBITDA increased 29% to
Baylin Technologies Q2 Earnings Call Highlights
Key Points
- Interested in Baylin Technologies Inc.? Here are five stocks we like better.
- Record backlog: Baylin Technologies’ backlog reached CAD 61 million in Q2 2026, up from CAD 20.4 million
Voyager Technologies Q2 Earnings Call Highlights
Key Points
- Interested in Voyager Technologies, Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 15% year over year to $53 million, while bookings reached $113
Valneva Aktie: Ixchiq in Großbritannien nicht vorrätig
Das französisch-österreichische Biotech-Unternehmen Valneva bereitet sich auf die Vorlage seiner Geschäftszahlen für das erste…
Der Beitrag Valneva Aktie: Ixchiq in Großbritannien nicht vorrätig
NexGen Energy Q2 Earnings Call Highlights
Key Points
- Interested in NexGen Energy? Here are five stocks we like better.
- Rook I construction remains on schedule and within budget: NexGen completed key milestones, including commissioning
Insmed Aktie: BRINSUPRI-Umsatz steigt um 49 Prozent
Insmed hat am Donnerstag Zahlen für das zweite Quartal vorgelegt, die den Markt überzeugten.…
Der Beitrag Insmed Aktie: BRINSUPRI-Umsatz steigt um 49 Prozent erschien zuerst auf kapitalmarktexperten
Hawaiian Electric Industries Q2 Earnings Call Highlights
Key Points
- Interested in Hawaiian Electric Industries, Inc.? Here are five stocks we like better.
- Hawaiian Electric reported $123.2 million in Q2 net income, or $0.71 per share, boosted by a
Globus Medical Q2 Earnings Call Highlights
Key Points
- Interested in Globus Medical, Inc.? Here are five stocks we like better.
- Q2 revenue rose 6% to $789.6 million, while record non-GAAP EPS increased 56% to $1.34 and adjusted EBITDA
Genesis Energy Q2 Earnings Call Highlights
Genesis Energy (NYSE:GEL) said its second-quarter 2026 performance was broadly in line with internal expectations, with some results slightly ahead, as the company continued to reshape its balance
Verastem Q2 Earnings Call Highlights
Key Points
- Interested in Verastem, Inc.? Here are five stocks we like better.
- Q2 revenue improved: Verastem reported $25.1 million in AVMAPKI FAKZYNJA CO-PACK product revenue and a $15 million
Aurora Cannabis Shareholders Approve Board as Fiscal 2026 Results Beat Outlook
Key Points
- Interested in Aurora Cannabis Inc.? Here are five stocks we like better.
- Shareholders approved all proposals, including a five-member board, the election of Aurora’s director
Beauty Health Q2 Earnings Call Highlights
Key Points
- Interested in The Beauty Health Company? Here are five stocks we like better.
- Second-quarter results were mixed: Revenue fell 7.8% year over year to $72.1 million, pressured by
Novavax Q2 Earnings Call Highlights
Novavax (NASDAQ:NVAX) reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in